** Juno Therapeutics up more than 13 pct onreported AstraZeneca interest in immuno-oncology sector
** Traders cite Astra CEO saying in interview to Bloombergthat saying companies like Juno could be of potential interest
** Bounce in Juno shares lifts peers Bellicum Pharma, up 5.2 pct, and Affimed, up 4.4 pct
** CEO adds in interview that potential CAR-T cell therapiesmust be able to manage side effects before any Astra purchase
(RM: vikram.subhedar.thomsonreuters.com@reuters.net)